Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Acquired In-Process R&D Written Off in Acquisitions by Year
Acquired In-Process R&D (IPR&D) Written Off in Acquisitions (legacy) ($M) ($M)
Amgen Acquired In-Process R&D Written Off in Acquisitions: $0M in FY2023. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-14) ↗
Reported in Form 10-K Consolidated Statements of Cash Flows / Acquisitions Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired In-Process R&D (IPR&D) Written Off in Acquisitions (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 0 | -100.0% | Form 10-K (filed 2024-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,505 | – | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-16) ↗ |
Cite this data
StockData. (2026). Amgen Acquired In-Process R&D Written Off in Acquisitions ($M), annual FY2019–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/rd-iprd-exp
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.